Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2020

Open Access 01-12-2020 | Prostate Cancer | Review

Clinical implication of prognostic and predictive biomarkers for castration-resistant prostate cancer: a systematic review

Authors: Shengri Tian, Zhen Lei, Zuo Gong, Zhonghai Sun, Dongyuan Xu, Minhu Piao

Published in: Cancer Cell International | Issue 1/2020

Login to get access

Abstract

Background

Diagnosis of metastatic castrate resistant prostate cancer (mCRPC) with current biomarkers is difficult and often results in unnecessary invasive procedures as well as over-diagnosis and over-treatment. There are a number of prognostic biomarkers for CRPC, but there are no validated predictive biomarkers to guide in clinical decision-making. Specific biomarkers are needed that enable to understand the natural history and complex biology of this heterogeneous malignancy, identify early response to treatment outcomes and to identify the population of men most likely to benefit from the treatment. In this systematic review, we discuss the existing literature for the role of biomarkers in CRPC and how they aid in the prognosis, treatment selection and survival outcomes.

Methods

We performed a literature search on PubMed and EMBASE databases from January 2015 through February 2020 in accordance to Preferred Reporting Items for Systematic Review and Meta-Analysis guidelines. Articles were assessed to identify relevant observational studies and randomized controlled trials regarding biomarkers which aid in identifying progression to mCRPC as well as predictive biomarkers which help in treatment selection.

Results

We identified 3640 number of hits of which 58 articles were found to be relevant. Here we addressed biomarkers in the context of prognosis, prediction and patient selection of therapy. These biomarkers were found to be effective as prognostic or predictive factors under variety of conditions. The higher levels for all these biomarkers were associated with shorter median OS and sometimes PFS. Lower amounts of biomarkers in serum or urine were associated with prolonged survival outcomes, longer time to CRPC development or CRPC progression and longer median follow-up irrespective of any therapy.

Conclusion

We observed that the biomarkers included in our study predicted clinically relevant survival outcomes and treatment exposure. Though the current biomarkers are prognostic when measured prior to initiating treatment, not all are validated as predictive markers in post treatment setting. A greater understanding of biomarkers in CRPC is need of the hour for development of more personalized approach to maximize benefit and minimize harm in men with CRPC.
Literature
1.
2.
3.
Terada N, Akamatsu S, Kobayashi T, Inoue T, Ogawa O, Antonarakis ES. Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications. Ther Adv Med Oncol. 2017;9:565–73.PubMedPubMedCentralCrossRef
4.
Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71:630–42.PubMedCrossRef
5.
6.
Komura K, Sweeney CJ, Inamoto T, Ibuki N, Azuma H, Kantoff PW. Current treatment strategies for advanced prostate cancer. Int J Urol. 2018;25:220–31.PubMedCrossRef
7.
8.
Huang JG, Campbell N, Goldenberg SL. PSA and beyond: biomarkers in prostate cancer. 8.
9.
10.
McGrath S, Christidis D, Perera M, Hong SK, Manning T, Vela I, et al. Prostate cancer biomarkers: are we hitting the mark? Prostate Int. 2016;4:130–5.PubMedPubMedCentralCrossRef
11.
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T Immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–22.PubMedCrossRef
12.
Kelly WK, Halabi S, Carducci M, George D, Mahoney JF, Stadler WM, et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. JCO. 2012;30:1534–40.CrossRef
13.
Parker C, Heinrich D, O’Sullivan JM, Fossa S, Chodacki A, Demkow T, et al. Overall survival benefit of radium-223 chloride (Alpharadin™) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a phase III randomized trial (ALSYMPCA). Eur J Cancer. 2011;47:3.CrossRef
14.
Dancey JE, Dobbin KK, Groshen S, Jessup JM, Hruszkewycz AH, Koehler M, Biomarkers Task Force of the NCI Investigational Drug Steering Committee, et al. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res. 2010;16:1745–55.PubMedCrossRef
15.
16.
17.
18.
Sieuwerts AM, Onstenk W, Kraan J, Beaufort CM, Van M, De Laere B, et al. AR splice variants in circulating tumor cells of patients with castration-resistant prostate cancer: relation with outcome to cabazitaxel. Mol Oncol. 2019;13:1795–807.PubMedPubMedCentralCrossRef
19.
Belderbos BPS, Sieuwerts AM, Hoop EO, Mostert B, Kraan J, Hamberg P, et al. Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer. Eur J Cancer. 2019;121:48–54.PubMedCrossRef
20.
Cattrini C, Rubagotti A, Zinoli L, Cerbone L, Zanardi E, Capaia M, et al. Role of circulating tumor cells (CTC), Androgen receptor full length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a prospective cohort of castration-resistant metastatic prostate cancer patients. Cancers. 2019;11:1365.PubMedCentralCrossRef
21.
Qu Y, Dai B, Ye D, Kong Y, Chang K, Jia Z, et al. Constitutively active AR-V7 plays an essential role in the development and progression of castration-resistant prostate cancer. Sci Rep. 2015;5:7654.PubMedPubMedCentralCrossRef
22.
Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Zhu Y, et al. Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide. J Clin Oncol. 2017;35:2149–56.PubMedPubMedCentralCrossRef
23.
Qu F, Xie W, Nakabayashi M, Zhang H, Jeong SH, Wang X, et al. Association of AR-V7 and prostate-specific antigen RNA levels in blood with efficacy of abiraterone acetate and enzalutamide treatment in men with prostate cancer. Clin Cancer Res. 2017;23:726–34.PubMedCrossRef
24.
Carles J, Castellano D, Méndez-Vidal M-J, Mellado B, Saez M-I, González Del Alba A, et al. Circulating tumor cells as a biomarker of survival and response to radium-223 therapy: experience in a cohort of patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2018;16:e1133–9.PubMedCrossRef
25.
De Kruijff IE, Sieuwerts AM, Onstenk W, Kraan J, Smid M, Van MN, et al. Circulating tumor cell enumeration and characterization in metastatic castration-resistant prostate cancer patients treated with cabazitaxel. Cancers. 2019;11:1212.PubMedCentralCrossRef
26.
Bitting RL, Healy P, Halabi S, George DJ, Goodin M, Armstrong AJ. Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer. Urol Oncol. 2015;33(110):e1–9.
27.
Josefsson A, Linder A, Flondell Site D, Canesin G, Stiehm A, Anand A, et al. Circulating tumor cells as a marker for progression-free survival in metastatic castration-naïve prostate cancer. Prostate. 2017;77:849–58.PubMedCrossRef
28.
29.
Vaishampayan UN, Podgorski I, Heilbrun LK, Lawhorn-Crews JM, Dobson KC, Boerner J, et al. Biomarkers and bone imaging dynamics associated with clinical outcomes of oral cabozantinib therapy in metastatic castrate-resistant prostate cancer. Clin Cancer Res. 2019;25:652–62.PubMedCrossRef
30.
Lara PN, Plets M, Tangen C, Gertz E, Vogelzang NJ, Hussain M, et al. Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: results from SWOG S0421. Cancer Treat Res Commun. 2018;16:18–23.PubMedPubMedCentralCrossRef
31.
Naito M, Ukai R, Hashimoto K. Bone scan index can be a useful biomarker of survival outcomes in patients with metastatic castration-resistant prostate cancer treated with radium-223. Cancer Rep. 2019;2:e1203.
32.
Dizdarevic S, Jessop M, Begley P, Main S, Robinson A. 223Ra-Dichloride in castration-resistant metastatic prostate cancer: improving outcomes and identifying predictors of survival in clinical practice. Eur J Nucl Med Mol Imaging. 2018;45:2264–73.PubMedPubMedCentralCrossRef
33.
Miyoshi Y, Sakamoto S, Kawahara T, Uemura K, Yokomizo Y, Uemura H. Correlation between automated bone scan index change after cabazitaxel and survival among men with castration-resistant prostate cancer. Urol Int. 2019;103:279–84.PubMedCrossRef
34.
Hammerich K, Donahue T, Rosner I, Cullen J, Kuo H-C, Hurwitz L, et al. Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer. Urol Oncol Semin Orig Invest. 2017;35:460.e21–8.
35.
Anand A, Morris MJ, Larson SM, Minarik D, Josefsson A, Helgstrand JT, et al. Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide. EJNMMI Res. 2016;6:23.PubMedPubMedCentralCrossRef
36.
Onal C, Sedef AM, Kose F, Oymak E, Guler OC, Sumbul AT, et al. The hematologic parameters in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate. Future Oncol. 2019;15:1469–79.PubMedCrossRef
37.
Loubersac T, Nguile-Makao M, Pouliot F, Fradet V, Toren P. Neutrophil-to-lymphocyte ratio as a predictive marker of response to abiraterone acetate: a retrospective analysis of the COU302 study. Eur Urol Oncol. 2019;3:298–305.PubMedCrossRef
38.
Tatenuma T, Kawahara T, Hayashi N, Hasumi H, Makiyama K, Nakaigawa N, et al. The pretherapeutic neutrophil-to-lymphocyte ratio for docetaxel-based chemotherapy is useful for predicting the prognosis of japanese patients with castration-resistant prostate cancer. Biomed Res Int. 2019;2019:2535270.PubMedPubMedCentralCrossRef
39.
40.
Lorente D, Mateo J, Templeton AJ, Zafeiriou Z, Bianchini D, Ferraldeschi R, et al. Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. Ann Oncol. 2015;26:750–5.PubMedCrossRef
41.
Koo KC, Lee JS, Ha JS, Han KS, Lee KS, Hah YS, et al. Optimal sequencing strategy using docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant prostate cancer: utilization of neutrophil-to-lymphocyte ratio. World J Urol. 2019;37:2375–84.PubMedCrossRef
42.
Song W, Kwon GY, Kim JH, Lim JE, Jeon HG, Il Seo S, et al. Immunohistochemical staining of ERG and SOX9 as potential biomarkers of docetaxel response in patients with metastatic castration-resistant prostate cancer. Oncotarget. 2016;7:83735–43.PubMedPubMedCentralCrossRef
43.
Berg KD, Røder MA, Thomsen FB, Vainer B, Gerds TA, Brasso K, et al. The predictive value of ERG protein expression for development of castration-resistant prostate cancer in hormone-naïve advanced prostate cancer treated with primary androgen deprivation therapy. Prostate. 2015;75:1499–509.PubMedCrossRef
44.
Ando K, Sakamoto S, Takeshita N, Fujimoto A, Maimaiti M, Saito S, et al. Higher serum testosterone levels predict poor prognosis in castration-resistant prostate cancer patients treated with docetaxel. Prostate. 2020;80:247–55.PubMedCrossRef
45.
Hashimoto K, Tabata H, Shindo T, Tanaka T, Hashimoto J, Inoue R, Sapporo Medical University Urologic Oncology Consortium (SUOC), et al. Serum testosterone level is a useful biomarker for determining the optimal treatment for castration-resistant prostate cancer. Urol Oncol. 2019;37:485–91.PubMedCrossRef
46.
Shiota M, Kashiwagi E, Murakami T, Takeuchi A, Imada K, Inokuchi J, et al. Serum testosterone level as possible predictive marker in androgen receptor axis-targeting agents and taxane chemotherapies for castration-resistant prostate cancer. Urol Oncol. 2019;37:180.e19–24.CrossRef
47.
Wang Y, Dai B, Ye D-W. Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients. Asian J Androl. 2017;19:178–83.PubMedCrossRef
48.
Yasuoka S, Yuasa T, Ogawa M, Komai Y, Numao N, Yamamoto S, et al. Risk factors for poor survival in metastatic castration-resistant prostate cancer treated with cabazitaxel in Japan. Anticancer Res. 2019;39:5803–9.PubMedCrossRef
49.
Kosaka T, Hongo H, Mizuno R, Oya M. Risk stratification of castration-resistant prostate cancer patients treated with cabazitaxel. Mol Clin Oncol. 2018;9:683–8.PubMedPubMedCentral
50.
Belderbos BPS, de Wit R, Hoop EO, Nieuweboer A, Hamberg P, van Alphen RJ, et al. Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel. Oncotarget. 2017;8:106468–74.PubMedPubMedCentralCrossRef
51.
Pei X, Wu K, Sun Y, Gao X, Gou X, Xu J, Chinese Prostate Cancer Consortium, et al. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: multicenter validation in patients from the Chinese Prostate Cancer Consortium. Urol Oncol. 2020;38:2.e11–7.CrossRef
52.
Yang K-F, Lee H-Y, Wu W-J, Huang C-H, Chou Y-H, Huang C-N, et al. Prediction for survival following docetaxel-based chemotherapy in Taiwanese men with castration-resistant metastatic prostate cancer. Urol Sci. 2015;26:271–6.CrossRef
53.
Lin T-T, Chen Y-H, Wu Y-P, Chen S-Z, Li X-D, Lin Y-Z, et al. Risk factors for progression to castration-resistant prostate cancer in metastatic prostate cancer patients. J Cancer. 2019;10:5608–13.PubMedPubMedCentralCrossRef
54.
Ji G, Song G. Rapidly decreasing level of prostate-specific antigen during initial androgen deprivation therapy is a risk factor for early progression to castration-resistant prostate cancer. Ann Oncol. 2017;28:x77.CrossRef
55.
He M, Liu H, Cao J, Wang Q, Xu H, Wang Y. Predicting castration-resistant prostate cancer after combined androgen blockade. Oncotarget. 2017;8:105458–62.PubMedPubMedCentralCrossRef
56.
Kuo KF, Hunter-Merrill R, Gulati R, Hall SP, Gambol TE, Higano CS, et al. Relationships between times to testosterone and prostate-specific antigen rises during the first off-treatment interval of intermittent androgen deprivation are prognostic for castration resistance in men with nonmetastatic prostate cancer. Clin Genitourin Cancer. 2015;13:10–6.PubMedCrossRef
57.
Hamano I, Hatakeyama S, Narita S, Takahashi M, Sakurai T, Kawamura S, et al. Impact of nadir PSA level and time to nadir during initial androgen deprivation therapy on prognosis in patients with metastatic castration-resistant prostate cancer. World J Urol. 2019;37:2365–73.PubMedCrossRef
58.
Fukuoka K, Teishima J, Nagamatsu H, Inoue S, Hayashi T, Mita K, et al. Predictors of poor response to first-generation anti-androgens as criteria for alternate treatments for patients with non-metastatic castration-resistant prostate cancer. Int Urol Nephrol. 2020;52:77–85.PubMedCrossRef
59.
Kodama H, Hatakeyama S, Narita S, Takahashi M, Sakurai T, Kawamura S, et al. Clinical characterization of low prostate-specific antigen on prognosis in patients with metastatic castration-naive prostate cancer. Clin Genitourin Cancer. 2019;17:e1091–8.PubMedCrossRef
60.
Sathekge M, Bruchertseifer F, Vorster M, Lawal IO, Knoesen O, Mahapane J, et al. Predictors of overall and disease-free survival in metastatic castration-resistant prostate cancer patients receiving 225Ac-PSMA-617 radioligand therapy. J Nucl Med. 2020;61:62–9.PubMedCrossRef
61.
Rahbar K, Boegemann M, Yordanova A, Eveslage M, Schäfers M, Essler M, et al. PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival. Eur J Nucl Med Mol Imaging. 2018;45:12–9.PubMedCrossRef
62.
Ahmadzadehfar H, Schlolaut S, Fimmers R, Yordanova A, Hirzebruch S, Schlenkhoff C, et al. Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy. Oncotarget. 2017;8:103108–16.PubMedPubMedCentralCrossRef
63.
Alvim CM, Mansinho A, Paiva RS, Brás R, Semedo PM, Lobo-Martins S, et al. Prognostic factors for patients treated with abiraterone. Future Sci OA. 2019;6:FSO436.PubMedPubMedCentralCrossRef
64.
Schiff JP, Cotogno P, Feibus A, Steinwald P, Ledet E, Lewis B, et al. Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer. BMC Cancer. 2019;19:524.PubMedPubMedCentralCrossRef
65.
Houédé N, Beuzeboc P, Gourgou S, Tosi D, Moise L, Gravis G, et al. Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France. BMC Cancer. 2015;15:222.PubMedPubMedCentralCrossRef
66.
Chang L-W, Hung S-C, Wang S-S, Li J-R, Yang C-K, Chen C-S, et al. Abiraterone acetate and enzalutamide: similar efficacy in treating post docetaxel metastatic castration-resistant prostate cancer: single center experience. Anticancer Res. 2019;39:3901–8.PubMedCrossRef
67.
Fan L, Dong B, Chi C, Wang Y, Gong Y, Sha J, et al. Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors. BMC Urol. 2018;18:110.PubMedPubMedCentralCrossRef
68.
Miyake H, Hara T, Tamura K, Sugiyama T, Furuse H, Ozono S, et al. Independent association between time to prostate-specific antigen (PSA) nadir and PSA progression-free survival in patients with docetaxel-naïve, metastatic castration-resistant prostate cancer receiving abiraterone acetate, but not enzalutamide. Urol Oncol. 2017;35:432–7.PubMedCrossRef
69.
Papazoglou D, Wannesson L, Berthold D, Cathomas R, Gillessen S, Rothermundt C, et al. Enzalutamide in patients with castration-resistant prostate cancer progressing after docetaxel: retrospective analysis of the swiss enzalutamide named patient program. Clin Genitourin Cancer. 2017;15:e315–23.PubMedCrossRef
70.
Armstrong AJ, Lin P, Higano CS, Iversen P, Sternberg CN, Tombal B, et al. Prognostic association of prostate-specific antigen decline with clinical outcomes in men with metastatic castration-resistant prostate cancer treated with enzalutamide in a randomized clinical trial. Eur Urol Oncol. 2019;2:677–84.PubMedCrossRef
71.
Kobayashi T, Namitome R, Hirata YU, Shiota M, Imada K, Kashiwagi E, et al. Serum prognostic factors of androgen-deprivation therapy among Japanese men with de novo metastatic prostate cancer. Anticancer Res. 2019;39:3191–5.PubMedCrossRef
72.
Hiew K, Hart CA, Ali A, Elliott T, Ramani V, Sangar V, et al. Primary mutational landscape linked with pre-docetaxel lactate dehydrogenase levels predicts docetaxel response in metastatic castrate-resistant prostate cancer. Eur Urol Focus. 2019;5:831–41.PubMedCrossRef
73.
Gravis G, Boher J-M, Fizazi K, Joly F, Priou F, Marino P, et al. Prognostic factors for survival in noncastrate metastatic prostate cancer: validation of the glass model and development of a novel simplified prognostic model. Eur Urol. 2015;68:196–204.PubMedCrossRef
74.
Mori K, Kimura T, Onuma H, Kimura S, Yamamoto T, Sasaki H, et al. Lactate dehydrogenase predicts combined progression-free survival after sequential therapy with abiraterone and enzalutamide for patients with castration-resistant prostate cancer. Prostate. 2017;77:1144–50.PubMedCrossRef
75.
Miyoshi Y, Ohtaka M, Kawahara T, Ohtake S, Yasui M, Uemura K, et al. Prediction of time to castration-resistant prostate cancer using low-molecular-weight protein tyrosine phosphatase expression for men with metastatic hormone-naïve prostate cancer. Urol Int. 2019;102:37–42.PubMedCrossRef
76.
Ohtaka M, Miyoshi Y, Kawahara T, Ohtake S, Yasui M, Uemura K, et al. Low-molecular-weight protein tyrosine phosphatase expression as a prognostic factor for men with metastatic hormone-naïve prostate cancer. Urol Oncol. 2017;35:607.e9–14.CrossRef
77.
78.
Fuerea A, Baciarello G, Patrikidou A, Albigès L, Massard C, Di Palma M, et al. Early PSA response is an independent prognostic factor in patients with metastatic castration-resistant prostate cancer treated with next-generation androgen pathway inhibitors. Eur J Cancer. 2016;61:44–51.PubMedCrossRef
79.
Van Gils MPMQ, Stenman UH, Schalken JA, Schröder FH, Luider TM, Lilja H, et al. Innovations in serum and urine markers in prostate cancer current European research in the P-Mark project. Eur Urol. 2005;48:1031–41.PubMedCrossRef
80.
Saylor PJ, Armstrong AJ, Fizazi K, Freedland S, Saad F, Smith MR, et al. New and emerging therapies for bone metastases in genitourinary cancers. Eur Urol. 2013;63:309–20.PubMedCrossRef
81.
Van Soest RJ, Templeton AJ, Vera-Badillo FE, Mercier F, Sonpavde G, Amir E, et al. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials. Ann Oncol. 2015;26:743–9.PubMedCrossRef
82.
Leibowitz-Amit R, Templeton AJ, Omlin A, Pezaro C, Atenafu EG, Keizman D, et al. Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2014;25:657–62.PubMedPubMedCentralCrossRef
83.
Templeton AJ, Pezaro C, Omlin A, McNamara MG, Leibowitz-Amit R, Vera-Badillo FE, et al. Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer. 2014;120:3346–52.PubMedCrossRef
84.
85.
Park S-W, Kim JH, Lee HJ, Shin DH, Lee SD, Yoon S. The expression of androgen receptor and its variants in human prostate cancer tissue according to disease status, and its prognostic significance. World J Mens Health. 2019;37:68–77.PubMedCrossRef
86.
Galletti G, Portella L, Tagawa ST, Kirby BJ, Giannakakou P, Nanus DM. Circulating tumor cells in prostate cancer diagnosis and monitoring: an appraisal of clinical potential. Mol Diagn Ther. 2014;18:389–402.PubMedPubMedCentralCrossRef
87.
Kodama K, Tojjar D, Yamada S, Toda K, Patel CJ, Butte AJ. Ethnic differences in the relationship between insulin sensitivity and insulin response: a systematic review and meta-analysis. Diabetes Care. 2013;36:1789–96.PubMedPubMedCentralCrossRef
Metadata
Title
Clinical implication of prognostic and predictive biomarkers for castration-resistant prostate cancer: a systematic review
Authors
Shengri Tian
Zhen Lei
Zuo Gong
Zhonghai Sun
Dongyuan Xu
Minhu Piao
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2020
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-020-01508-0

Other articles of this Issue 1/2020

Cancer Cell International 1/2020 Go to the issue

Primary research

Prognostic role of alternative splicing events in head and neck squamous cell carcinoma

Primary research

Characterization and comparison of genomic profiles between primary cancer cell lines and parent atypical meningioma tumors

Primary research

Depletion of histone methyltransferase KMT9 inhibits lung cancer cell proliferation by inducing non-apoptotic cell death

Primary research

Construction of a novel gene-based model for prognosis prediction of clear cell renal cell carcinoma

Primary research

C-phycocyanin inhibits epithelial-to-mesenchymal transition in Caski cells

Correction

Correction to: NF-κB and pSTAT3 synergistically drive G6PD overexpression and facilitate sensitivity to G6PD inhibition in ccRCC
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits